Atyr Pharma Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
22.9%projected annual EPS growth
Analyst Coverage
7analysts covering
FY EPS (est.)
-$0.41next fiscal year
Monitoring Framework
Key Performance Indicators
Cash, Cash Equivalents, Restricted Cash and Available-for-Sale Investments Quarterly68.3MTarget: Sufficient to fund operations for at least one year
Quarterly Net Loss Quarterly-10.8MTarget: Narrowing loss through operational cost discipline
Watch Items
- IND Application Submission for New Phase 3 Pulmonary Sarcoidosis TrialTrigger: Submission timeline target of June 2026Action: Monitor SEC filings and press releases for confirmation of IND submission and FDA clearance to initiate the trial.
- Phase 2 EFZO-CONNECT Trial Enrollment CompletionTrigger: Target completion of enrollment in the first half of 2026Action: Track corporate updates for confirmation of full enrollment in the SSc-ILD trial.
- Nasdaq Minimum Bid Price ComplianceTrigger: Maintain bid price above $1.00 before November 30, 2026Action: Monitor stock price; evaluate potential implementation of a reverse stock split if organic compliance is not achieved.
Research as of 19 Jun 2026